These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23727022)

  • 61. Oncogene-Driven Induction of Orthotopic Cholangiocarcinoma in Mice.
    Plantureux C; Paillet J; Autret G; Pérez-Lanzón M; Kroemer G; Maiuri MC; Pol J
    Methods Mol Biol; 2024; 2769():99-108. PubMed ID: 38315392
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New and Old Key Players in Liver Cancer.
    Cuesta ÁM; Palao N; Bragado P; Gutierrez-Uzquiza A; Herrera B; Sánchez A; Porras A
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138981
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Novel Mouse Model of Intrahepatic Cholangiocarcinoma Induced by Azoxymethane.
    Shirakami Y; Kato J; Ohnishi M; Taguchi D; Maeda T; Ideta T; Kubota M; Sakai H; Tomita H; Tanaka T; Shimizu M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834032
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NOTCH signalling - a core regulator of bile duct disease?
    Martinez Lyons A; Boulter L
    Dis Model Mech; 2023 Sep; 16(9):. PubMed ID: 37605966
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular profiling reveals potential targets in cholangiocarcinoma.
    Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
    World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin.
    Testa U; Pelosi E; Castelli G
    Technol Cancer Res Treat; 2023; 22():15330338221128689. PubMed ID: 36872875
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.
    Vanaroj P; Chaijaroenkul W; Na-Bangchang K
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):551-558. PubMed ID: 36853304
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Notch signaling, hypoxia, and cancer.
    Guo M; Niu Y; Xie M; Liu X; Li X
    Front Oncol; 2023; 13():1078768. PubMed ID: 36798826
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
    Calvisi DF; Boulter L; Vaquero J; Saborowski A; Fabris L; Rodrigues PM; Coulouarn C; Castro RE; Segatto O; Raggi C; van der Laan LJW; Carpino G; Goeppert B; Roessler S; Kendall TJ; Evert M; Gonzalez-Sanchez E; Valle JW; Vogel A; Bridgewater J; Borad MJ; Gores GJ; Roberts LR; Marin JJG; Andersen JB; Alvaro D; Forner A; Banales JM; Cardinale V; Macias RIR; Vicent S; Chen X; Braconi C; Verstegen MMA; Fouassier L;
    Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):462-480. PubMed ID: 36755084
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination.
    Gromowski T; Lukacs-Kornek V; Cisowski J
    Cancer Cell Int; 2023 Jan; 23(1):3. PubMed ID: 36609378
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
    Zhao L; Wang Y; Tian T; Rao X; Dong W; Zhang J; Yang Y; Tao Q; Peng F; Shen C; Wang S; Liu H; Zeng X; Zhou W
    Hepatol Int; 2022 Dec; 16(6):1339-1352. PubMed ID: 36123506
    [TBL] [Abstract][Full Text] [Related]  

  • 74. RNA-sequencing reveals the expression profiles of tsRNAs and their potential carcinogenic role in cholangiocarcinoma.
    Li YK; Yan LR; Wang A; Jiang LY; Xu Q; Wang BG
    J Clin Lab Anal; 2022 Oct; 36(10):e24694. PubMed ID: 36098712
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.
    Li M; Zhou X; Wang W; Ji B; Shao Y; Du Q; Yao J; Yang Y
    J Clin Transl Hepatol; 2022 Aug; 10(4):700-710. PubMed ID: 36062286
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
    Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A γ-Secretase Inhibitor Attenuates Cell Cycle Progression and Invasion in Human Oral Squamous Cell Carcinoma: An In Vitro Study.
    Pongjantarasatian S; Nowwarote N; Rotchanakitamnuai V; Srirodjanakul W; Saehun R; Janebodin K; Manokawinchoke J; Fournier BPJ; Osathanon T
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012128
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.
    Zheng Q; Zhang B; Li C; Zhang X
    Front Oncol; 2022; 12():850732. PubMed ID: 35372014
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review).
    Vanaroj P; Chaijaroenkul W; Na-Bangchang K
    Mol Clin Oncol; 2022 Mar; 16(3):66. PubMed ID: 35154706
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma.
    Marcus R; Ferri-Borgogno S; Hosein A; Foo WC; Ghosh B; Zhao J; Rajapakshe K; Brugarolas J; Maitra A; Gupta S
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.